Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
March 13, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
March 12, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
February 27, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
February 22, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
February 14, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
November 21, 2023 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...